Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) has provided updates regarding 2019 and its positive outlook heading into 2020
  • In September, the company achieved two significant milestones with its U.S. partner beginning its phase 3 trial and the U.S. FDA granting all three of its orphan drug applications for NNZ-2591
  • Now that NNZ-2591 has been granted in Europe, Neuren now has patents until 2034 in the U.S., Europe and Japan
  • Neuren is currently up 4.35 per cent with shares trading for $2.40 apiece

Neuren Pharmaceuticals (NEU) has provided updates regarding 2019 and its positive outlook heading into 2020.

“In September we highlighted two very important milestones that were anticipated for the fourth quarter of 2019,” Executive Chairman Richard Treagus commented.

These two milestones include its U.S. partner ACADIA beginning the LAVENDER phase 3 trial in Rett Syndrome, and the U.S. Food and Drug Administration granting all three of its orphan drug applications for Phelan-McDermid, Angelman and Pitt Hopkins syndromes.

Now that NNZ-2591 has been granted in Europe, Neuren now has patents to 2034 in each of the key markets of the U.S., Europe and Japan.

Over the course of 2019 Neuren, assisted by Torreya, has actively engaged with third parties both in and outside of the U.S. to evaluate potential transactions.

The company has also received a number of proposals which have led to more detailed discussions. Throughout these discussions, Neuren has remained clear on what it considers to be an acceptable range of possible outcomes.

In recent weeks the process has advanced further with a level of interest that the Neuren Board regards as meaningful and appropriate.

While there is no certainty as of yet, these discussions form a good basis to extend the Torreya process into 2020.

Neuren is now approaching the end of the year in a strong position, advancing two valuable drugs to treat five childhood disorders for which there are currently no approved therapies.

Neuren is currently up 4.35 per cent with shares trading for $2.40 at 12:38 pm AEDT.

NEU by the numbers
More From The Market Herald
The Market Herald Video

" Optiscan Imaging (ASX:OIL) signs distribution partnership for China

Optiscan Imaging (OIL) joins forces with a strategic distribution partner in China for its ViewnVivo device.
The Market Herald Video

" Imugene (ASX:IMU) confirms “favourable” survival outcome in HER-Vaxx phase two trial

Imugene (ASX:IMU) has reported positive final overall data from its phase two study of HER-Vaxx in…
The Market Herald Video

" Dimerix (ASX:DXB) closes recruitment for REMAP-CAP study

Dimerix (ASX:DXB) has formally closed recruitment of moderate state COVID-19 patients for REMAP-CAP's renin angiotensin system…
The Market Herald Video

" Starpharma (ASX:SPL) expands research program with Genentech

Starpharma (ASX:SPL) expands its research agreement with Genentech for its drug delivery technology, DEP.